Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19
Cousins et al.,
Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for..,
medRxiv, doi:10.1101/2022.07.02.22277181 (Preprint)
PSM retrospective 64,349 COVID-19 patients in the USA, showing metformin associated with lower ICU admission and mechanical ventilation.
risk of mechanical ventilation, 54.0% lower, OR 0.46, p = 0.007, treatment 2,498, control 2,497, propensity score matching, RR approximated with OR.
|
risk of ICU admission, 56.0% lower, OR 0.44, p < 0.001, treatment 2,498, control 2,497, propensity score matching, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Cousins et al., 6 Jul 2022, retrospective, USA, preprint, 8 authors.
Contact:
cousinsh@stanford.edu, russ.altman@stanford.edu, yuan.luo@northwestern.edu, congle@stanford.edu.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.02.22277181; this version posted July 6, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Integrative analysis of viral entry networks and clinical outcomes identifies a protective
role for spironolactone in severe COVID-19
Henry Cousins1,2,*, Adrienne Sarah Kline3, Chengkun Wang4,5, Yuanhao Qu4,5, Mengdi Wang6,
Russ Altman1,4,7,8,*, Yuan Luo3,*, Le Cong4,5,*
1 Department of Biomedical Data Science, Stanford University School of Medicine, Stanford,
CA, USA
2 Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA,
USA
3 Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University,
Chicago, IL, USA
4 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
5 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
6 Department of Electronic Engineering, Princeton University, Princeton, NJ, USA
7 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
8 Department of Bioengineering, Stanford University, Stanford, CA, USA
* Correspondence to: cousinsh@stanford.edu (H.C.), russ.altman@stanford.edu (R.A.),
Yuan.Luo@northwestern.edu (Y.L.), congle@stanford.edu (L.C.)
ABSTRACT
Treatment strategies that target host entry factors have proven an effective means of impeding
viral entry in HIV and may be more robust to viral evolution than drugs targeting viral proteins
directly. High-throughput functional screens provide an unbiased means of identifying genes
that influence the infection of host cells, while retrospective cohort analysis can measure the
real-world, clinical potential of repurposing existing therapeutics as antiviral treatments. Here,
we combine these two powerful methods to identify drugs that alter the clinical course of
COVID-19 by targeting host entry factors. We demonstrate that integrative analysis of genomewide CRISPR screening datasets enables network-based prioritization of drugs modulating viral
entry, and we identify three common medications (spironolactone, quetiapine, and carvedilol)
based on their network proximity to putative host factors. To understand the drugs’ real-world
impact, we perform a propensity-score-matched, retrospective cohort study of 64,349 COVID-19
patients and show that spironolactone use is associated with improved clinical prognosis,
measured by both ICU admission and mechanical ventilation rates. Finally, we show that
spironolactone exerts a dose-dependent inhibitory effect on viral entry in a human lung epithelial
cell line. Our results suggest that spironolactone may improve clinical outcomes in COVID-19
through tissue-dependent inhibition of viral entry. Our work further provides a potential approach
to integrate functional genomics with real-world evidence for drug repurposing.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1
medRxiv preprint doi: https://doi.org/10.1101/2022.07.02.22277181; this version posted July 6, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse..
cousins
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit